- Home
- NRXS vs CODX Comparison
NRXS vs CODX Comparison
Compare NRXS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRXS | CODX |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 15.6M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NRXS | CODX |
|---|---|---|
| Price | $2.75 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.00 | $2.25 |
| AVG Volume (30 Days) | 49.4K | ★ 1.5M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,362,320.00 | $507,892.00 |
| Revenue This Year | $31.05 | N/A |
| Revenue Next Year | $137.61 | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.89 | N/A |
| 52 Week Low | $1.33 | $0.23 |
| 52 Week High | $6.20 | $1.55 |
Technical Indicators
Market Signals| Indicator | NRXS | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 46.20 |
| Support Level | $2.50 | $0.34 |
| Resistance Level | $2.76 | $0.41 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 45.47 | 22.21 |
Price Performance
Historical ComparisonAbout NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.